#Switzerland #ADC Therapeutics #ZYNLONTA #Lausanne #antibody drug conjugates

ADC Therapeutics Q1 2026 Financial Summary

ADC Therapeutics SA, a leader in antibody drug conjugates (ADCs), recently reported its financial outcomes for the first quarter of 2026, showcasing significant updates and projections regarding its flagship product, ZYNLONTA (loncastuximab tesirine-lpyl). The financial report reveals a net product revenue of $20 million for Q1 2026, marking an increase from $17.4 million in the same quarter of 2025. This growth in revenue is largely attributed to higher sales volumes and pricing fluctuations.

Operational Updates

In his remarks, Ameet Mallik, CEO of ADC Therapeutics, stated, "We witnessed increased momentum in our ZYNLONTA program during the first quarter. Looking ahead, we anticipate several crucial developments."

Among these upcoming milestones are the topline results from the LOTIS-5 trial, expected in the second quarter of 2026, and comprehensive results by year-end. The LOTIS-5 Phase 3 trial studies ZYNLONTA in combination with rituximab for treating large B-cell lymphoma. Positive results may expedite the submission of a supplemental Biologics License Application (sBLA) to the FDA within the year, potentially paving the way for early 2027 approval for newly diagnosed patients.

The company is also actively managing the LOTIS-7 trial, which is investigating ZYNLONTA combined with glofitamab in patients with relapsed or refractory dual large B-cell lymphoma. Enrolment is expected to complete by mid-2026, with influential data sharing planned for late 2026.

Additionally, investigator-initiated trials (IITs) are ongoing, evaluating ZYNLONTA's efficacy in treating various B-cell malignancies including follicular and marginal zone lymphoma. Results from these trials are expected between late 2026 and mid-2027.

Financial Performance

In terms of expenditures, research and development expenses significantly dropped to $19.9 million in Q1 2026 from $28.9 million in the prior year. This decline reflects optimization in external costs and reallocation of personnel involved in clinical supply functions to focus on commercial manufacturing endeavors.

Selling and marketing expenses saw an uptick to $12.7 million due to increased wages and advertising efforts. Meanwhile, general administrative expenses remained relatively steady at $9.9 million.

Despite these operational advances, ADC Therapeutics recorded a net loss of $33 million for the quarter, which is a reduction from the $38.6 million net loss reported for Q1 2025. The adjusted net loss stands at $19.7 million compared to $24 million from the previous year, demonstrating a positive trend in expense management.

Cash Position

As of March 31, 2026, the company reported cash and cash equivalents totaling $231 million. This healthy cash position provides a liquidity runway that extends well into 2028, supporting continued investment in R&D and commercial activities for ZYNLONTA.

Forward Outlook

As ADC Therapeutics moves forward, the anticipated topline results from LOTIS-5 and the advancements in LOTIS-7 present a strong potential for extending ZYNLONTA’s treatment applications across various B-cell cancers. The company’s strategic focus on enhancing both revenue streams and operational efficiency positions it favorably as it seeks to increase its market share in the competitive ADC landscape.

A conference call for stakeholders will be held today to further discuss these results and upcoming strategies, reflecting ADC Therapeutics' commitment to transparency and growth. Investors are invited to participate and gain insights directly from the company’s leadership.

In summary, ADC Therapeutics’ financial and operational updates for Q1 2026 highlight the company’s dynamic approach to expanding its influence in the oncology sector, particularly through its innovative ADC technology with ZYNLONTA at the forefront.